News

Hematologists and ophthalmologists could work together for earlier diagnoses, research findings indicate

Dr. Arnaldo Espaillat decided to undergo ZEISS PRESBYOND and shares how his own experience led him to expand his refractive portfolio with this corneal-based approach for patients without cataracts.

The May 4 event, themed around Star Wars, will feature the latest innovations, foster open discussions, and provide a collaborative environment for networking and learning, with sessions covering IOLs, oculoplastics, glaucoma, retina therapy, and refractive surgical options.

The study considered the economic disease burden on both the patient and the caregivers, the first such study of its kind.

The approval makes ILM-Blue the first DORC posterior dye product available in China, according to a press release from Zeiss.

Researchers assessed the costs to patients and caregivers in Germany, Bulgaria and the US

This year, the COPHy meeting moves beyond retina, addressing uveitis, neuro-ophthalmology and glaucoma in Seville, Spain

Urcosimod (formerly known as OK-101) has been shown to be stable for over 2 and a half years in single-use ampoules used for administration of the drug to patients.

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

Lab TRIACTIV is powered by “advanced cationic liposomal technology” for dry eye relief.

The authors examined vascular and neural structures in the eye, assessing the foveal avascular zone and choroidal thickness

A resurgence in this IOL technology could create new possibilities in refractive correction

The study assessed a large paediatric cohort for changes in spherical equivalent refraction, axial length, lens power and lens thickness

The approval makes ILM-Blue the first DORC posterior dye product available in China, according to a press release from Zeiss

Pantheon Vision’s bioengineered corneal implant aims to tackle issues with the success rate of human donated tissue.

Epi-on corneal crosslinking is advancing through innovations like supplemental oxygen, chemical oxygenation, and laser-assisted techniques.

AURN001 is Aurion Biotech's clinical-stage allogeneic cell therapy asset for corneal oedema secondary to corneal endothelial disease

The recall was conducted out of an abundance of caution after the company received reports of complications. The cause of said complications could not be immediately explained.

Aurion is developing AURN001, a clinical-stage allogeneic cell therapy asset, for corneal edema secondary to corneal endothelial disease.

Vision correction has evolved into a continuum of procedures suited for different stages of ocular maturity

The investigators conducted a prospective interventional study to determine the therapeutic anatomic and functional effects of one intravitreal dexamethasone implant in eyes with refractory diabetic macular edema.

Brazilian researchers conducted a study comparing two treatments for postoperative endophthalmitis. They found that pars plana vitrectomy followed by an intravitreal antibiotic injection (PPV + IVAIES) was more effective than using an intravitreal antibiotic injection alone (IVAI).

One intravitreal injection of the dexamethasone implant in patients with refractory DME induced significant anatomic and functional improvements, but these improvements only lasted for short periods of up to 4 months.

The approval makes ILM-Blue the first DORC posterior dye product available in China, according to a press release from Zeiss

The authors examined vascular and neural structures in the eye, assessing the foveal avascular zone and choroidal thickness